Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals is a clinical-stage ophthalmology biopharma, founded in 2015 in San Francisco, that develops therapies for dry eye syndrome, neurotrophic keratitis, and other ocular surface diseases. Following its $415 million acquisition by Viatris in January 2023, it operates as a wholly-owned subsidiary within Viatris's global ophthalmology portfolio.
- Company typePrivate
- Founded2015
- HeadquartersSan Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oyster Point Pharmaceuticals does
Oyster Point Pharmaceuticals is a clinical-stage, ophthalmology-focused pharmaceutical company founded in 2015 and headquartered in San Francisco, California. The firm was organized around the discovery, development, and commercialization of therapies for ocular surface diseases — including dry eye syndrome, neurotrophic keratitis, and persistent epithelial defects — and was publicly listed on NASDAQ under the ticker OYST prior to its acquisition. The company's product and technology surface consisted of proprietary small-molecule and intranasal delivery approaches to corneal and ocular surface conditions, though the input data does not enumerate named product SKUs.
In January 2023, Viatris Inc. acquired Oyster Point for $415 million in cash, simultaneously closing a related $280 million acquisition of Family Life Sciences, an Indian drug development platform, to anchor an integrated ophthalmology and drug-development buildout within Viatris. Following the transaction, Oyster Point operates as a wholly-owned subsidiary of Viatris (NASDAQ: VTRS), with commercial distribution handed off to Viatris's global pharmaceutical distribution network.
Historically, Oyster Point's capital structure reflected venture-stage scaling rather than established cash flow: three disclosed private rounds totaling approximately $235.8 million (a 2017 round of $22 million led by NEA and Versant Ventures, a 2019 round of $93 million led by Flying L Partners and Invus, and a 2020 round of approximately $120.8 million), with insider leadership including CEO Jeffrey Nau, CFO Mark Murray, and CCO John Snisarenko. Standalone revenue, product-level sales, and segment margin data are not separately disclosed in available source material, reflecting both its pre-acquisition, single-product commercial stage and its post-deal absorption into a larger parent's segment reporting.
Oyster Point Pharmaceuticals firmographics
Firmographics- Name
- Oyster Point Pharmaceuticals
- Legal name
- Oyster Point Pharma
- Website
- https://oysterpointrx.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Oyster Point Pharmaceuticals is a clinical-stage ophthalmology biopharma, founded in 2015 in San Francisco, that develops therapies for dry eye syndrome, neurotrophic keratitis, and other ocular surface diseases. Following its $415 million acquisition by Viatris in January 2023, it operates as a wholly-owned subsidiary within Viatris's global ophthalmology portfolio.
- Ownership category
- akta.pro rank
Oyster Point Pharmaceuticals industry classification
Industry- Product category
- Ophthalmology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where Oyster Point Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Oyster Point Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Distribution channels1 record
Oyster Point Pharmaceuticals product offering
Product offeringCore offering
Oyster Point Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of therapies for ocular surface diseases, including dry eye syndrome, neurotrophic keratitis, and persistent epithelial defects. Following its January 2023 acquisition by Viatris Inc. for $415 million, it operates as a wholly-owned subsidiary within Viatris's expanded ophthalmology portfolio.
Product overview
Oyster Point Pharmaceuticals was a pharmaceutical company focused on ophthalmology, specifically developing therapies for ocular surface diseases. In January 2023, the company was acquired by Viatris Inc. for $415 million as part of Viatris's strategy to expand its ophthalmology portfolio. The source data does not provide specific details on individual product names or offerings from Oyster Point Pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Products and services
- Ophthalmology Pharmaceutical Portfolio
Companies that use Oyster Point Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Oyster Point Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Oyster Point Pharmaceuticals partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights4 records
Oyster Point Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Allergan (AbbVie): Allergan, now part of AbbVie, markets Restasis and a broad ophthalmology portfolio including dry eye and ocular surface therapies, making it the leading incumbent competitor in Oyster Point's core therapeutic categories.
- Bausch + Lomb (Bausch Health): Bausch + Lomb is a major ophthalmology franchise selling Xiidra for dry eye disease along with surgical, vision care, and consumer eye health products, directly competing for prescriber share in ocular surface disease.
- Regeneron Pharmaceuticals: Regeneron markets Eylea, the leading anti-VEGF therapy for retinal diseases, and has built a deep ophthalmology commercial capability that competes in adjacent physician channels and indication spaces.
- Alcon: Alcon is the largest pure-play ophthalmology company globally, spanning surgical, vision care, and pharmaceutical products for dry eye and other ocular surface conditions; it acquired Aerie Pharmaceuticals, signaling continued ophthalmology specialty-pharma expansion.
- Novartis Pharmaceuticals (Ophthalmology): Novartis operates a substantial ophthalmology franchise including Lucentis and emerging gene therapies for inherited retinal disease, competing for prescriber relationships and formulary access relevant to ocular surface products.
Direct peers
- Kala Pharmaceuticals: Kala Pharmaceuticals is a small-cap ophthalmology company developing and commercializing therapies for ocular surface diseases, including dry eye and post-surgical inflammation, closely mirroring Oyster Point's specialty-pharma model and indications.
- Aldeyra Therapeutics: Aldeyra Therapeutics is a clinical-stage biotech developing treatments for ocular inflammatory diseases including dry eye disease, sharing Oyster Point's clinical-stage profile and ocular surface focus.
- Sun Pharma (Tarsier Pharma / Cequa): Sun Pharma markets Cequa, an FDA-approved dry eye therapy, and also acquired Ocular Technologies via Tarsier, making it a directly competitive player in the ophthalmology specialty pharma space where Oyster Point operates.
- Nicox: Nicox is a European ophthalmology specialty pharma company developing therapies for glaucoma and ocular surface diseases, representing a similarly sized, indication-focused comparable to Oyster Point.
- Aerie Pharmaceuticals: Aerie Pharmaceuticals was a small ophthalmology specialty pharma focused on glaucoma and dry eye (with ophthalmic drying agent pipeline) before being acquired by Alcon in 2022 - a close precedent for clinical-stage ophthalmology specialty-pharma M&A.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Oyster Point Pharmaceuticals social profiles
Digital presenceOyster Point Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oyster Point Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles8 records
Oyster Point Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oyster Point Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oyster Point Pharmaceuticals
What does Oyster Point Pharmaceuticals do?
Oyster Point Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of therapies for ocular surface diseases, including dry eye syndrome, neurotrophic keratitis, and persistent epithelial defects. Following its January 2023 acquisition by Viatris Inc. for $415 million, it operates as a wholly-owned subsidiary within Viatris's expanded ophthalmology portfolio.
Is Oyster Point Pharmaceuticals a public or private company?
Oyster Point Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.
When was Oyster Point Pharmaceuticals founded?
Oyster Point Pharmaceuticals was founded in 2015. It employs 101 to 250 people.
Where is Oyster Point Pharmaceuticals based?
Oyster Point Pharmaceuticals is headquartered in San Francisco, United States, in the North America region.
Who are Oyster Point Pharmaceuticals's main competitors?
Broad incumbents on record are Allergan (AbbVie), Bausch + Lomb (Bausch Health), Regeneron Pharmaceuticals, Alcon and Novartis Pharmaceuticals (Ophthalmology). Direct peers are Kala Pharmaceuticals, Aldeyra Therapeutics, Sun Pharma (Tarsier Pharma / Cequa), Nicox and Aerie Pharmaceuticals.
Does Oyster Point Pharmaceuticals have an API?
No public API is recorded for Oyster Point Pharmaceuticals.
What industry is Oyster Point Pharmaceuticals in?
Oyster Point Pharmaceuticals's product category is Ophthalmology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.